Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search

		Submit


Smoking & Tobacco Use


Section Navigation
			
			CDC Home








For Healthcare ProvidersEspañol (Spanish)|Print										Related Pages
										Physician with arms folded holding a stethescope
**CDC encourages clinicians to continue to report possible cases of e-cigarette, or vaping, product use-associated lung injury (EVALI) to their local or state health department for further investigation.**
If EVALI is suspected, health care providers should ask about the use of e-cigarette, or vaping, products in a confidential and nonjudgmental manner.   The most critical step in assessing EVALI is to ask patients about recent use of e-cigarette, or vaping, products. If product use is confirmed, ask about the types of substances used (e.g., [tetrahydrocannabinol] THC and nicotine) and where they were obtained.
Interim guidance for healthcare providers for managing patients with suspected EVALI can be found here, and is summarized in a management algorithm and discharge readiness checklist. Hospitalized patients should be documented as clinically stable for 24-48 hours prior to discharge and have close post-discharge follow-up (optimally within 48 hours of discharge) as outlined in this interim guidance.
ICD-10-CM coding guidance for healthcare encounters related to EVALI are also available.For Healthcare Providers
For Health Departments
Frequently Asked Questions
Resources
		On This Page
			OverviewEvaluationInfluenza ConsiderationsTreatment and Follow-upDiscontinue E-cigarette, or Vaping, Product UseOverviewEmergency department (ED) visits related to e-cigarette, or vaping, products continue to decline, after sharply increasing in August 2019 and peaking in September.
National and state data from patient reports and product sample testing show tetrahydrocannabinol (THC)-containing e-cigarette, or vaping, products, particularly from informal sources like friends, family, or in-person or online dealers, are linked to most EVALI cases and play a major role in the outbreak.
Vitamin E acetate is strongly linked to the EVALI outbreak. Vitamin E acetate has been found in product samples tested by FDA and state laboratories and in patient lung fluid samples tested by CDC from geographically diverse states. Vitamin E acetate has not been found in the lung fluid of people that do not have EVALI.
Evidence is not sufficient to rule out the contribution of other chemicals of concern, including chemicals in either THC or non-THC products, in some of the reported EVALI cases.CDC will continue to update guidance related to EVALI as appropriate.EvaluationEVALI remains a diagnosis of exclusion because, at present, no specific test or marker exists for its diagnosis, and evaluation should be guided by clinical judgment. Rapid recognition of EVALI patients by healthcare providers is critical to reduce severe outcomes.
Influenza cannot be distinguished from EVALI by signs, symptoms, clinical features at presentation (medical examination), or testing. Acute respiratory illness in a patient with a history of e-cigarette/vaping and THC exposure could be caused by influenza viruses, other respiratory infections, EVALI, or all of the above.
*Patient Interview*
When evaluating patients with respiratory symptoms (e.g., cough, chest pain, and shortness of breath), gastrointestinal symptoms (e.g., abdominal pain, nausea, vomiting, stomach pain, and diarrhea), or nonspecific constitutional symptoms (e.g., fever, chills, and weight loss):
Ask about recent use of e-cigarette, or vaping, products in a confidential and nonjudgmental manner.
If product use is confirmed, the types of substances used (e.g., THC, nicotine) and where they were obtained should be ascertained.
Learn best practices for the patient interview with Don’t Forget to Ask [PDF – 129kb].*Physical Examination*
Assess vital signs and pulse oximetry.*Laboratory Testing and Imaging*
Laboratory testing should be guided by clinical findings.
A chest radiograph (CXR) should be considered for patients with a history of e-cigarette, or vaping, product use, who have respiratory or gastrointestinal symptoms, particularly when chest pain, dyspnea, or decreased oxygen saturation (<95% while breathing room air) are present.
Healthcare providers should evaluate for causes of community-acquired pneumonia according to established guidelines as indicated by imaging findings.Top of PageInfluenza Considerations*Influenza Testing and Empiric Antimicrobial, including Antiviral Treatment*
Influenza testing should be strongly considered, particularly during influenza season. It might be difficult to differentiate EVALI, a diagnosis of exclusion, from influenza or community-acquired pneumonia on initial assessment, and EVALI might co-occur with respiratory infections.
Treatment with empiric antimicrobials, including antivirals, should be considered in accordance with established guidelines and local microbiology and resistance patterns for community-acquired pneumonia.
Antiviral treatment also can be considered for any previously healthy, symptomatic outpatient not at high risk for influenza complications, who is diagnosed with confirmed or suspected influenza, on the basis of clinical judgment, if treatment can be initiated within 48 hours of illness onset.
Healthcare providers should emphasize the importance of annual influenza vaccination for all persons aged ≥6 months, including patients who use e-cigarette, or vaping, products.
It is not known whether patients with EVALI are at higher risk for severe complications of influenza or other respiratory infections. In addition, administration of pneumococcal vaccine should be considered for patients with a history of EVALI according to current guidelines.
Check out Key Facts About Seasonal Flu Vaccine for more information.Top of PageTreatment and Follow-up*Consideration of Outpatient Management*
Some patients with history of e-cigarette, or vaping, product use who are evaluated for respiratory, gastrointestinal, or constitutional symptoms might be candidates for outpatient management.
Candidates for outpatient management should have normal oxygen saturation (≥95% while breathing room air), no respiratory distress, no comorbidities that might compromise pulmonary reserve, reliable access to care, strong social support systems, and should be able to ensure follow up within 24–48 hours of initial evaluation and to seek medical care promptly if respiratory symptoms worsen; in some cases, patients who initially had mild symptoms experienced a rapid worsening of symptoms within 48 hours.
Hospital admission should be strongly considered for patients with concurrent illness such as influenza and potential EVALI, especially if respiratory distress, comorbidities that compromise pulmonary reserve, or decreased oxygen saturation (<95% while breathing room air) are present.*Corticosteroid Treatment*
Corticosteroids might be helpful in treating EVALI.
Use of corticosteroids for the treatment of EVALI in the outpatient setting has not been well studied and should be considered with caution. Corticosteroids might worsen respiratory infections commonly seen in the outpatient setting.
In published reports primarily including hospitalized patients, most patients with EVALI who received corticosteroids had rapid improvement; dosages have been previously described.
Some patients who have not received corticosteroids have also had clinical improvement with cessation of e-cigarette, or vaping, product use, and comparative studies have not been conducted.*Discharge Planning*
Hospitalized patients should be documented as clinically stable for 24–48 hours prior to discharge.
Healthcare providers should assure patients have social support and access to mental health and substance use disorder services.
Medication reconciliation and patient counseling should be provided by the inpatient pharmacist to help ensure medication adherence.
Healthcare providers should confirm patients have a follow-up appointment with a primary care provider or pulmonology specialist, optimally within 48 hours of discharge.
Healthcare providers can use the EVALI Discharge Readiness Checklist [PDF – 110 KB] to help plan for safe discharge.*Post- Discharge Follow-Up*
Patients discharged from the hospital after inpatient treatment for EVALI should have a follow-up visit with a primary care provider or pulmonology specialist, optimally within 48 hours.
The follow-up evaluation should include: clinical assessment to confirm that the patient’s respiratory status is stable; ongoing education about EVALI; ensuring adherence with medication regimens such as tapering of corticosteroids (if prescribed at the time of hospital discharge); reinforcing the importance of abstinence from e-cigarette, or vaping, product use; facilitating connection to outpatient care by all providers or services indicated by patients’ medical history or conditions; connecting patients to needed social, mental health, and substance use disorder resources; and establishing connections to necessary services.
Longer-term pulmonary follow-up should generally occur within 2–4 weeks after discharge (often at completion of the corticosteroid taper) to assess pulmonary function and resolution of radiographic findings.
Additional follow-up testing 1–2 months after discharge might include spirometry, diffusing capacity of the lung for carbon monoxide (DLCO), and CXR.
Patients who have experienced prolonged immobilization during hospitalization (particularly those with intensive care unit-related deconditioning and muscle atrophy) might benefit from physical therapy. Ongoing engagement with addiction medicine and mental health services should be considered as indicated.
Healthcare providers should also advise patients with a history of EVALI to return as soon as possible if they develop new or worsening respiratory symptoms, with or without fever, for early evaluation with influenza testing and early initiation of antiviral or antibiotic treatment, as indicated.*Considerations at Point of Care*
Consider posting reminders or signage (poster for clinical settings available in English [print-only PDF – 299 KB] or Spanish [print-only PDF – 296 KB]) to encourage conversation between patients and providers about use of e-cigarette, or vaping, products.Report cases of EVALI to your state or local health department.Top of PageDiscontinue E-cigarette, or Vaping, Product UseCDC and FDA recommend that people not use THC-containing e-cigarette, or vaping, products, particularly from informal sources like friends, or family, or in-person or online dealers.
Resuming use of e-cigarette, or vaping, products during recovery from EVALI has the potential to cause slowed recovery, recurrence of symptoms, or further lung injury.
Adults using nicotine-containing e-cigarette, or vaping, products as an alternative to cigarettes should not go back to smoking; they should weigh all available information and consider using FDA-approved smoking cessation medications. If they choose to use e-cigarettes as an alternative to cigarettes, they should completely switch from cigarettes to e-cigarettes and not partake in an extended period of dual use of both products that delays quitting smoking completely. They should contact their healthcare professional if they need help quitting tobacco products, including e-cigarettes, as well as if they have concerns about EVALI.
Persons engaging in ongoing cannabis use that leads to significant impairment or distress should seek evidence-based treatment from a healthcare professional.
Additional Resources for Healthcare ProvidersTop of PageIf you have questions about CDC’s investigation into the lung injuries associated with use of e-cigarette, or vaping, products, contact CDC-INFO or call 1-800-232-4636.
							
					
							Last Reviewed:  March 17, 2020						Source: 	Office on Smoking and Health, National Center for Chronic Disease Prevention and Health Promotion
					Facebook
        Twitter
        LinkedIn
        Syndicate homeHomeOffice on Smoking and Health (OSH)plus iconOSH Partners with StatesFunding Opportunity AnnouncementsInteragency Committee on Smoking and Healthplus iconMembership RosterNewsroomStay ConnectedOrganizationSmoking & Tobacco Use FeaturesQuit Smokingplus iconHow to Quitplus iconBenefits of QuittingCessation Materials for Tobacco Control Programsplus iconNational Quitline Data WarehouseBasic Informationplus iconHealth Effectsplus iconCancerHeart Disease and StrokeChronic Obstructive Pulmonary Disease (COPD)Smoking During PregnancyEquality in Smoking & Disease: Nobody Wins!Electronic Cigarettesplus iconAbout Electronic Cigarettes (E-Cigarettes)Quick Facts on the Risks of E-cigarettes for Kids, Teens, and Young AdultsMenthol Tobacco Productsplus iconMenthol Tobacco Products are a Public Health ProblemMenthol Smoking and Related Health DisparitiesAddressing Menthol Tobacco ProductsHeated Tobacco ProductsSecondhand Smokeplus iconGoing Smokefree MattersHealth Effects of Secondhand SmokePolicy and Legislationplus iconLegislationRegulationYouth Tobacco PreventionRelated ResourcesCommercial Tobacco and Health Equityplus iconBlack and African American Peopleplus iconHealth BurdenUnfair and Unjust Practices and ConditionsSecondhand SmokeQuitting TobaccoAmerican Indian and Alaska Native Peopleplus iconHealth BurdenUnfair and Unjust Practices and ConditionsSecondhand SmokeQuitting TobaccoAsian, Native Hawaiian, and Pacific Islander Peopleplus iconHealth BurdenUnfair and Unjust Practices and ConditionsQuitting TobaccoHispanic and Latino Peopleplus iconHealth BurdenUnfair and Unjust Practices and ConditionsSecondhand SmokeQuitting TobaccoLGBTQ+ Peopleplus iconHealth BurdenUnfair and Unjust Practices and ConditionsQuitting TobaccoPeople Across Geographic Regionsplus iconHealth BurdenUnfair and Unjust Practices and ConditionsSecondhand SmokeQuitting TobaccoPeople with Behavioral Health Conditionsplus iconHealth BurdenUnfair and Unjust Practices and ConditionsCommercial Tobacco Product Use and Behavioral Health Conditions can Affect Each OtherQuitting TobaccoPeople with Low Socioeconomic Statusplus iconHealth BurdenUnfair and Unjust Practices and ConditionsSecondhand SmokeQuitting TobaccoSecondhand Smokeplus iconGeneral InformationTrends and DisparitiesHealth ProblemsPreventing Exposure in the CommunityPreventing Exposure in the HomeSmokefree PoliciesResourcesSurgeon General's Reports on Smoking and Tobacco Useplus icon2020 SGR—Smoking Cessation2016 SGR—E-Cigarette Use Among Youth and Young AdultsHistorical ReportsA Brief HistoryArchiveData and Statisticsplus iconFast Facts and Fact Sheetsplus icon**Smoking and Cigarettes**Diseases and DeathHealth Effects of Cigarette SmokingTobacco-Related MortalityCigarette Smoking in the U.S.Adult DataCessationCost and ExpendituresEconomics**Smokeless Tobacco**Health EffectsProducts and MarketingSmokeless Tobacco Product Use in the United States**Other Tobacco Products**CigarsHookahsBidis and KreteksLow Yield Cigarettes**Secondhand Smoke****Youth Tobacco Use**Youth DataSmoking in the MoviesTrends in Tobacco Use Among Youth**Tobacco Industry**Tobacco Brand PreferencesIndustry MarketingSurveysplus iconNational Youth Tobacco Survey (NYTS)Alaska Native Adult Tobacco Survey Guidance ManualAmerican Indian Adult Tobacco SurveyScientific Evidence BriefsSTATE SystemMorbidity and Mortality Weekly Reports (MMWR)Vital SignsPatient Careplus iconPatient Care Settings and Smoking Cessationplus iconCardiovascular Care SettingsRespiratory Care SettingsCancer Care SettingsMaternal and Infant Care SettingsClinical Interventions to Treat Tobacco Use and Dependence Among AdultsClinical Cessation ToolsPatient Cessation MaterialsQuitlines and Other Cessation Support ResourcesClinical Education and TrainingE-Cigarettes and Patient CareState and Community Workplus iconTobacco Control Programsplus iconNetworking2Save: Co-op AgreementGuidelines and ResourcesProgram FundingPrograms in Actionplus iconAlabama in ActionIndiana in ActionKentucky in ActionNebraska in ActionNew York in ActionWest Virginia in ActionPromising Policies And Practices To Address Tobacco Use By Persons With Mental And Substance Use DisordersEvidence Based Guides for StatesState Fact SheetsTobacco Ingredient and Nicotine Reportingplus iconDescription of the LawsReporting InstructionsFederal Register NoticesLegal RequirementsFrequently Asked QuestionsKey TermsRecommended FormatsTobacco Counter-Marketing CampaignGlobal Tobacco Controlplus iconAbout GTSSThe GATS AtlasMultimedia & Toolsplus iconMedia Campaign Resource Center (MCRC)InfographicsShareable MediaPublication Catalog


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue